Processa Pharmaceuticals, Inc.PCSA決算レポート
Nasdaq · ヘルスケア · 医薬製剤
プロセッサファーマシューティカルズは臨床段階のバイオ医薬品企業で、十分に医療ニーズが満たされていない患者向けの革新的治療薬の開発に注力している。コアパイプラインは希少疾患、消化器疾患、皮膚疾患を対象とし、主に北米・欧州の医療市場で事業を展開している。
インサイダー取引
Net 90d: +$103.1K · buys $103.1K / sells $0期間:
種別:
役職:
| インサイダー | 役職 | 種別 | ||||
|---|---|---|---|---|---|---|
| 2026-04-30 | Wendy Guy | Chief Administrative Officer | Buy (open market) | 1.7K | $2.69 | $4.7K |
| 2026-04-30 | Sian Bigora | Chief Development Officer | Buy (open market) | 2.0K | $2.69 | $5.3K |
| 2026-04-30 | Patrick Lin | Chief Business - Strategy Off | Buy (open market) | 1.5K | $2.69 | $4.1K |
| 2026-04-30 | Ng George K | Chief Executive Officer | Buy (open market) | 2.0K | $2.69 | $5.5K |
| 2026-04-30 | David Young | Pres. Research & Development | Buy (open market) | 1.7K | $2.69 | $4.6K |
| 2026-04-30 | SKIBSTED RUSSELL | Chief Financial Officer | Buy (open market) | 2.2K | $2.69 | $5.9K |
| 2026-04-15 | David Young | Pres. Research & Development | Buy (open market) | 1.5K | $2.97 | $4.6K |
| 2026-04-15 | Sian Bigora | Chief Development Officer | Buy (open market) | 1.8K | $2.97 | $5.3K |
| 2026-04-15 | SKIBSTED RUSSELL | Chief Financial Officer | Buy (open market) | 2.0K | $2.97 | $5.9K |
| 2026-04-15 | Ng George K | Chief Executive Officer | Buy (open market) | 1.8K | $2.97 | $5.5K |
1–10 of 21
1 / 3 ページ